When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Myovant Sciences (MYOV) is a biotech that should be on everyone's radar. That's because it has been able to achieve positive results in several indications, with the most recent positive results coming out of the HERO study using relugolix to treat men with advanced prostate cancer. This late-stage study had met on the primary endpoint, which will allow the company to file an NDA to the FDA for eventual approval for this indication by Q2 of 2020. In addition, there are several other catalysts that are anticipated in the 1st half of 2020.